Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients
Condition(s):Polycystic Kidney DiseasesLast Updated:February 26, 2020Completed
Hide Studies Not Open or Pending
Condition(s):Polycystic Kidney DiseasesLast Updated:February 26, 2020Completed
Condition(s):Chronic Hemodialysis (ESRD)Last Updated:April 27, 2021Completed
Condition(s):Alzheimer DiseaseLast Updated:January 6, 2022Unknown status
Condition(s):Systolic Heart Failure Stage D (Disorder); Mitral RegurgitationLast Updated:January 6, 2022Unknown status
Condition(s):Hypertension, Pregnancy Induced; Hydralazine Adverse Reaction; Pre-eclampsia; Pre-eclampsia Superimposed Pre-existing HypertensionLast Updated:October 26, 2018Completed
Condition(s):HypertensionLast Updated:June 17, 2020Completed
Condition(s):Breast CancerLast Updated:March 4, 2015Withdrawn
Condition(s):Acute Heart Failure; Left Ventricular DysfunctionLast Updated:August 14, 2015Unknown status
Condition(s):Ovarian CancerLast Updated:September 21, 2007Unknown status
Condition(s):Rectal CancerLast Updated:March 4, 2015Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.